Moderna compared the flu vaccine, dubbed mRNA-1010, to a currently approved seasonal flu vaccine from GlaxoSmithKline called Fluarix.
Moderna said the safety findings were similar in the trial to previous ones, which found muscle pain, headache, fatigue, pain and swelling as the most common side effects of mRNA-1010.
Also on Wednesday, Moderna said it is ending a separate phase three trial on the first version of its flu vaccine. That study did not generate enough cases to provide efficacy data. Meanwhile, Moderna on Wednesday said it expects a decision from the Food and Drug Administration on its mRNA vaccine for respiratory syncytial virus in adults 60 and older by April. The FDA approved RSV vaccines for older adults from Pfizer and GSK in May.
"Our mRNA platform is working," Moderna CEO Stephane Bancel said in a press release."With today's positive phase 3 flu results, along with previous results in Covid and RSV, we are now three for three on advancing respiratory disease programs to positive phase 3 data." The company will hold a virtual event at 1 p.m. ET on Wednesday to discuss research and development updates with investors.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Pfizer and Moderna updated COVID vaccines approved by FDAThe U.S. Food and Drug Administration on Monday approved updated mRNA COVID vaccines from Moderna Inc. and Pfizer Inc. People five years of age and older are...
Baca lebih lajut »
Stocks making the biggest moves midday: Tesla, Qualcomm, Meta, Moderna and moreThese are the stocks posting the largest moves in midday trading.
Baca lebih lajut »
Moderna ties up with Immatics to boost cancer vaccine developmentModerna said on Monday it has struck a deal with German drug developer Immatics for developing cancer vaccines and therapies, and would pay $120 million in cash and additional milestone payments.
Baca lebih lajut »
Immatics shares rise on Moderna cancer collaborationImmatics NV shares gained more than 6% premarket on Monday after the company announced a collaboration with Moderna Inc. to research and develop new cancer...
Baca lebih lajut »
FDA approves updated Covid vaccines from Pfizer and Moderna as hospitalizations riseThe Biden administration said it expects the new Pfizer and Moderna vaccines targeting the omicron variant XBB.1.5 to be available in mid-September.
Baca lebih lajut »
New Pfizer and Moderna COVID shots approved by FDACDC is set to vote on the new shots Tuesday, but questions remain about costs for uninsured people.
Baca lebih lajut »